Azuna Health LLC Files SC 13D for BioAdaptives Inc.

TL;DR

**Azuna Health LLC just filed a 13D on BioAdaptives Inc. Ownership change incoming.**

AI Summary

Azuna Health LLC, through its filing on October 22, 2024, has reported a change in its beneficial ownership of BioAdaptives Inc. The filing indicates a shift in control or significant stake, with James Keener listed as the authorized contact for notices. The specific details of the transaction, including dollar amounts and exact percentage changes, are not fully detailed in this excerpt.

Why It Matters

This filing signals a potential shift in the ownership structure of BioAdaptives Inc., which could impact its strategic direction and shareholder value.

Risk Assessment

Risk Level: medium — SC 13D filings often indicate significant ownership changes or activist intentions, which can introduce volatility and uncertainty for the company and its stock.

Key Players & Entities

• Azuna Health LLC (company) — Filing person
• BioAdaptives Inc (company) — Subject company
• James Keener (person) — Authorized contact for notices

FAQ

Key Financial Figures

• $97,200 — ealth LLC were sold to BioAdaptives for $97,200. Item 4. Purpose of Transaction Supp

Filing Documents

• bdpt_sc13d.htm (SC 13D) — 35KB
• bdpt_ex1.htm (EX-1) — 22KB
• 0001640334-24-001554.txt ( ) — 59KB

Security and Issuer

Item 1. Security and Issuer Preferred Series C BioAdaptives Inc 2620 Regatta Dr, Suite 102 Las Vegas, NV 89128

Identity and Background

Item 2. Identity and Background (a) Azuna Health LLC (b) 2300 West Sahara Av Suite 800, Las Vegas, NV 89102 (c) Health products (d) No (e) No (f) NV LLC (g) (h)

Source and Amount of Funds or Other Considerations

Item 3. Source and Amount of Funds or Other Considerations Products that were owned by Azuna Health LLC were sold to BioAdaptives for $97,200.

Purpose of Transaction

Item 4. Purpose of Transaction Supplied BioAdaptives with products that they resell in exchange for Preferred Series C stock.

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer (a) 1,000,000 shares of Preferred Series C stock representing 100% of issued shares. (b) Azuna Health LLC owns 1,000,000 shares of the Preferred Series C stock representing 100% of the class. (c) No transactions have taken place since the original purchase. (d) N/A (e) N/A

Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer The transaction involved a simple purchase of products. Series C Preferred stock was implemented in 2022 specifically for BioAdaptives' purchases of products. Page 3

Material to Be Filed as Exhibits

Item 7. Material to Be Filed as Exhibits Purchase agreement BioAdaptives and Azuna Health Signed.pdf Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. 10/22/2024 Dated /s/James Keener Signature James Keener Sole Member Azuna Health LLC Name/Title The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

View Full Filing

View this SC 13D filing on SEC EDGAR